Figure 7.

CNI CsA promotes the growth of human renal tumors in vivo with decreased expression of CXCR3-B in tumor tissues. (A) Human renal cancer cells (786-0; 1.0 × 10⁶) were injected subcutaneously into immunodeficient (nu/nu) mice, which (n = 8 in each group) were treated either with CsA (10 mg/kg per d) or with vehicle. Treatment was continued for 30 d, and tumor volume was monitored at regular intervals using a digital caliper. Tumors were harvested 30 d after tumor injection. The data reflect three independent experiments. Columns are average value of tumor volume; bars are ±SD. *P < 0.05 versus vehicle-treated controls. (B) Total RNA was isolated from harvested tumor tissues (day 30) and reverse-transcribed. Fold change in CXCR3-B and CXCR3-A mRNA expression was measured by real-time PCR. Data reflect three independent experiments resulting from duplicate readings of three different samples. Columns are average value of CXCR3-B and CXCR3-A mRNA expression, bars are ±SD. *P < 0.05 versus vehicle-treated cells.